7.885
price down icon0.63%   -0.015
 
loading
Precedente Chiudi:
$7.90
Aprire:
$7.85
Volume 24 ore:
88,091
Relative Volume:
0.28
Capitalizzazione di mercato:
$167.32M
Reddito:
$155.00K
Utile/perdita netta:
$-30.01M
Rapporto P/E:
-4.7216
EPS:
-1.67
Flusso di cassa netto:
$-11.98M
1 W Prestazione:
+0.13%
1M Prestazione:
+4.39%
6M Prestazione:
+24.60%
1 anno Prestazione:
-33.31%
Intervallo 1D:
Value
$7.70
$8.10
Intervallo di 1 settimana:
Value
$7.60
$8.67
Portata 52W:
Value
$4.32
$12.72

Inmune Bio Inc Stock (INMB) Company Profile

Name
Nome
Inmune Bio Inc
Name
Telefono
(858) 964-3720
Name
Indirizzo
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Name
Dipendente
13
Name
Cinguettio
@INmuneBio
Name
Prossima data di guadagno
2025-03-25
Name
Ultimi documenti SEC
Name
INMB's Discussions on Twitter

Confronta INMB con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
INMB
Inmune Bio Inc
7.86 167.32M 155.00K -30.01M -11.98M -1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
505.65 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
566.02 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
631.43 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.01 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
247.88 24.70B 3.81B -644.79M -669.77M -6.24

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-28 Iniziato Rodman & Renshaw Buy
2024-10-21 Iniziato Alliance Global Partners Buy
2024-09-27 Iniziato Raymond James Outperform
2024-08-22 Iniziato Scotiabank Sector Outperform
2023-06-01 Iniziato Robert W. Baird Outperform
2022-05-24 Downgrade B. Riley Securities Buy → Neutral
2021-07-07 Reiterato Maxim Group Buy
2021-04-21 Iniziato B. Riley Securities Buy
2021-01-22 Reiterato Maxim Group Buy
2020-09-01 Iniziato BTIG Research Buy
2020-07-15 Reiterato H.C. Wainwright Buy
Mostra tutto

Inmune Bio Inc Borsa (INMB) Ultime notizie

pulisher
Apr 23, 2025

A stock that deserves closer examination: INmune Bio Inc (INMB) - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

(INMB) Technical Data - news.stocktradersdaily.com

Apr 23, 2025
pulisher
Apr 16, 2025

Inmune Bio Secures Favorable Patentability Opinion for CORDStrom™ - TipRanks

Apr 16, 2025
pulisher
Apr 16, 2025

INmune Bio secures key patent opinion for CORDStrom platform By Investing.com - Investing.com South Africa

Apr 16, 2025
pulisher
Apr 16, 2025

INmune Bio Receives Favorable Opinion from USPTO on CORDStrom Patent Application - marketscreener.com

Apr 16, 2025
pulisher
Apr 16, 2025

INmune Bio Inc. Achieves Key Patent Milestone for CORDStrom™ Cell Therapy Platform - Nasdaq

Apr 16, 2025
pulisher
Apr 16, 2025

INmune Bio secures key patent opinion for CORDStrom platform - Investing.com

Apr 16, 2025
pulisher
Apr 16, 2025

Patent Win: INmune Bio's Revolutionary Cell Therapy Secures 20+ Years Protection - Stock Titan

Apr 16, 2025
pulisher
Apr 16, 2025

INmune Bio Receives Favorable Patentability Opinion for CORDStro - GuruFocus

Apr 16, 2025
pulisher
Apr 15, 2025

INmune Bio (INMB) Partners with CGT Catapult for Large-Scale Cel - GuruFocus

Apr 15, 2025
pulisher
Apr 14, 2025

INmune Bio Partners with Cell and Gene Therapy Catapult - MSN

Apr 14, 2025
pulisher
Apr 14, 2025

INmune Bio (INMB) Partners to Enhance Cell Therapy Production - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

INmune Bio in pact with Cell and Gene Therapy Catapult (INMB) - Seeking Alpha

Apr 14, 2025
pulisher
Apr 14, 2025

INmune Bio, CGT Catapult Partner To Scale CORDStrom Manufacturing For Commercial Launch - Nasdaq

Apr 14, 2025
pulisher
Apr 14, 2025

INmune Bio Collaborating With Cell and Gene Therapy Catapult to Scale Manufacturing - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness - The Manila Times

Apr 14, 2025
pulisher
Apr 14, 2025

INmune Bio's Game-Changing Partnership Accelerates CORDStrom Production for 4,000 RDEB Patients - Stock Titan

Apr 14, 2025
pulisher
Apr 09, 2025

Inmune Bio Presents Alzheimer’s Trial Data at Conference - TipRanks

Apr 09, 2025
pulisher
Apr 07, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives $22.80 Average Price Target from Brokerages - Defense World

Apr 07, 2025
pulisher
Apr 06, 2025

Trend Tracker for (INMB) - news.stocktradersdaily.com

Apr 06, 2025
pulisher
Apr 04, 2025

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update - ADVFN

Apr 04, 2025
pulisher
Apr 01, 2025

INmune Bio Presents MINDFuL Trial Data At AD/PD 2025 - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

INmune Bio Presents Baseline Data From MINDFuL Phase II Trial In Early Alzheimer's Disease - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

INmune Bio presents early Alzheimer’s trial data at AD/PD - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study - The Manila Times

Apr 01, 2025
pulisher
Apr 01, 2025

INmune Bio presents early Alzheimer’s trial data at AD/PD By Investing.com - Investing.com UK

Apr 01, 2025
pulisher
Mar 31, 2025

Raymond James maintains INmune Bio stock with $23 target By Investing.com - Investing.com Australia

Mar 31, 2025
pulisher
Mar 31, 2025

Raymond James maintains INmune Bio stock with $23 target - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Raymond James Financial Inc. Takes Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

INmune Bio anticipates Alzheimer's trial results within 100 days while advancing therapeutic platforms - MSN

Mar 30, 2025
pulisher
Mar 29, 2025

INmune Bio, Inc. (NASDAQ:INMB) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025
pulisher
Mar 28, 2025

Scotiabank Remains a Buy on Inmune Bio (INMB) - The Globe and Mail

Mar 28, 2025
pulisher
Mar 28, 2025

INmune Bio (INMB) Eyes Landmark Developments in 2024 Amid Rising Financial Commitments - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Earnings call transcript: INmune Bio’s Q4 2024 results highlight innovation focus - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategi - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

INmune Bio Reports 2024 Financial Results and Clinical Progress - TipRanks

Mar 28, 2025
pulisher
Mar 27, 2025

Earnings call transcript: INmune Bio’s Q4 2024 results highlight innovation focus By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

INmune Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

INmune Bio Inc Reports Q4 EPS of -$0.53 and Revenue of $0.01 Mil - GuruFocus.com

Mar 27, 2025
pulisher
Mar 27, 2025

INMUNE BIO Earnings Results: $INMB Reports Quarterly Earnings - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

INmune Bio's Triple Threat: Alzheimer's Trial Fully Enrolled, FDA Designations Secured - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

(INMB) On The My Stocks Page - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

What to Expect from INmune Bio's Earnings - Benzinga

Mar 26, 2025
pulisher
Mar 24, 2025

INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025 - The Manila Times

Mar 24, 2025
pulisher
Mar 21, 2025

Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West + - Seeking Alpha

Mar 21, 2025
pulisher
Mar 20, 2025

INmune Bio (INMB) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 18, 2025

INmune Bio: CORDStrom Is A Game-Changer, As Investors Await Alzheimer's Results (INMB) - Seeking Alpha

Mar 18, 2025

Inmune Bio Inc Azioni (INMB) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Inmune Bio Inc Azioni (INMB) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Tesi Raymond Joseph
President and CEO
Sep 12 '24
Buy
6.38
15,380
98,048
1,554,106
Moss David J
Chief Financial Officer
Sep 12 '24
Buy
6.38
7,690
49,024
1,275,869
Juda Scott
Director
Jun 25 '24
Buy
7.27
5,000
36,350
71,603
$20.90
price up icon 1.36%
$69.80
price up icon 0.31%
$32.42
price down icon 0.60%
$24.00
price up icon 0.25%
$103.85
price down icon 0.51%
biotechnology ONC
$249.09
price down icon 0.47%
Capitalizzazione:     |  Volume (24 ore):